Description
Orforglipron, is a once-daily oral tablet developed by Eli Lilly for chronic weight management. It belongs to the same family of medicines as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) — known as GLP-1 receptor agonists — but it's different in two important ways: it's taken as a tablet rather than an injection, and it's a small, non-peptide molecule rather than a protein-based one. That second point is what makes a daily pill possible: peptide GLP-1s like semaglutide are broken down by stomach acid and therefore need either injection or a strict fasted morning routine. Orforglipron is chemically stable enough to be absorbed without those restrictions.
How it works
Orforglipron mimics the action of glucagon-like peptide-1 (GLP-1), a natural hormone your gut releases after eating. By activating GLP-1 receptors in the gut and brain, it helps the body regulate appetite, fullness and blood sugar. In day-to-day terms, people in clinical trials reported:
-
Less hunger and fewer food cravings
-
Feeling full sooner and staying full for longer
-
Easier portion control around structured meals
-
Steadier energy between meals
Who it may be suitable for
Eligibility will ultimately be confirmed by UK prescribing guidance once the MHRA issues a licence, but based on the US label and typical UK GLP-1 prescribing patterns, orforglipron is expected to be considered for:
-
Adults with a BMI of 30 or above (obesity), or
-
Adults with a BMI of 27 or above who also have a weight-related health condition (for example type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnoea)
-
People who would prefer an oral treatment to a weekly injection
-
People who struggle with the fasted-morning dosing requirements of Rybelsus
As with Wegovy and Mounjaro, orforglipron is intended as part of a structured plan that also includes a reduced-calorie diet and increased physical activity — not a standalone fix.
Side Effects
As with other GLP-1 medicines, the most common side effects in trials were gastrointestinal and usually strongest during dose increases:
-
Nausea, indigestion or reflux
-
Bloating or belching
-
Constipation or diarrhoea
-
Reduced appetite (this is also the intended effect)
-
Headache, dizziness or fatigue in the early weeks
In ATTAIN-1 (clinical trail), between 5.3% and 10.3% of participants stopped treatment due to side effects, compared with 2.7% on placebo. Most symptoms eased as the dose stabilised.
Comfort tips (typical GLP-1 guidance)
-
Eat smaller, slower meals and stop at comfortable fullness
-
Prioritise lean protein, fibre and fluids; keep very fatty or spicy foods modest
-
Avoid lying flat immediately after eating if you're prone to reflux
-
Gentle walks can help with bloating
Additional Info
Serious safety information
Foundayo (The US version) carries a US boxed warning regarding thyroid C-cell tumours, based on findings in animal studies. This is a class warning shared by other GLP-1 medicines and has not been confirmed in humans, but the medicine is not recommended for anyone with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2. Other precautions, consistent with the wider GLP-1 class, include pancreatitis, gallbladder problems, and the potential for low blood sugar when combined with insulin or sulfonylureas. UK-specific precautions will be confirmed in the MHRA-approved Summary of Product Characteristics (SmPC) once the medicine is licensed here.
Directions
-
Once-daily tablet, swallowed whole with or without food
-
Can be taken at any time of day — no fasted-morning or 30-minute water rule (a key practical difference from Rybelsus)
-
The dose is increased in steps over several weeks, starting at the lowest dose and moving up only if the previous dose is well tolerated
-
Missed a dose? Take it as soon as you remember, unless your next dose is due soon — in which case skip the missed one and continue. Never double up.
-
If you stop taking it for a while and want to restart, your prescriber may recommend starting again at a lower dose rather than resuming at your previous one
FAQs
Is orforglipron availab le on the NHS?
No — it is not available privately or on the NHS in the UK yet. Even after any future MHRA licence, NHS availability would require a separate appraisal by the National Institute for Health and Care Excellence (NICE), which typically takes an additional 6–12 months after MHRA approval.
Can I buy orforglipron online now?
No. Any website or social media account offering orforglipron for sale in the UK is doing so unlawfully, and the product cannot be guaranteed to be genuine. Buying unlicensed prescription medicines online carries real risks — no quality control, unknown ingredients, and no legal recourse if something goes wrong.
Is it better than Wegovy or Mounjaro?
It's too early to say with certainty — there's been no direct head-to-head trial. Based on existing published data, injectable Mounjaro produces the largest average weight loss, followed by injectable Wegovy, with orforglipron modestly behind both. However, orforglipron is the only one taken as a once-daily tablet without food or water restrictions, which matters to people who'd rather not inject or who travel frequently.
How is it different from Rybelsus (oral semaglutide)?
Rybelsus must be taken on an empty stomach first thing in the morning, with no more than 120 ml of plain water, and you have to wait 30 minutes before eating, drinking or taking other medicines. Orforglipron has none of those restrictions — it can be taken any time of day, with or without food. Rybelsus is also currently only licensed in the UK for type 2 diabetes, not weight management.
Can I put my name on a waiting list?
We're not maintaining a waiting list for unlicensed medicines. The most reliable way to stay informed is to subscribe to our newsletter, where we post updates as UK licensing and availability develop. In the meantime, if you'd like to start a weight management treatment now, our weight loss service offers consultations for Wegovy and Mounjaro.
What happens if I stop taking orforglipron?
Based on evidence from other GLP-1 medicines, stopping treatment typically leads to some weight regain over time, particularly without sustained changes to diet and activity. The ATTAIN-MAINTAIN trial specifically looked at using orforglipron to maintain weight loss after stopping injectable GLP-1s — that's a relevant use case once it's available.
Does it cause hair loss?
Rapid weight loss of any kind can sometimes lead to temporary hair shedding (telogen effluvium). This has been reported with other GLP-1 medicines, and it usually resolves as weight stabilises. It was not flagged as a specifically elevated concern in the ATTAIN-1 publication.
What They Say About Us...
Great service, the follow up phone call to ensure that I was getting the correct medication was appreciated. Would yes 24 HR Pharmacy again.
Excellent customer service and prompt communication. My enquiry was resolved quickly, and my order was delivered ahead of time.
The service I received was faultless. Sehar is very knowledgeable and supportive in her consultation. The service was quick and easy to use.